PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry – FDA

Опубликовано 3 октября, 201817 декабря, 2018 frozencat

Обновление руководства FDA:

Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry

Руководство замещает Adaptive Design Clinical Trials for Drugs and Biologics – 2010.

Рубрики: Блог

Навигация по записям

Предыдущая запись: Определение объема выборки для исследований биоэквивалентности с использованием компьютерного моделирования
Следующая запись: Работа с данными в IBM SPSS: присвоение меток переменным из другого источника

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170803 170706
IMG-20170806-WA0014
20180816 140357
20170803 001141
IMG-20170730-WA0005
20180815 171426
  • FIBRYGA
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-24 By FDA
  • Competitive Generic Therapy Approvals
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-24 By FDA
  • Pfizer-BioNTech COVID-19 Vaccine
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-24 By FDA
  • Moderna COVID-19 Vaccine
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2025-06-24 By FDA
  • Human medicines European public assessment report (EPAR): Beyonttra, acoramidis, Date of authorisation: 10/02/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Human medicines European public assessment report (EPAR): Miglustat Gen.Orph, miglustat, Date of authorisation: 09/11/2017, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Laboratory Information Bulletins
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-24 By FDA
  • Human medicines European public assessment report (EPAR): Imuldosa, ustekinumab, Date of authorisation: 12/12/2024, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Human medicines European public assessment report (EPAR): Aripiprazole Sandoz, aripiprazole, Date of authorisation: 20/08/2015, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Human medicines European public assessment report (EPAR): Orgovyx, relugolix, Date of authorisation: 29/04/2022, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 12, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Date of authorisation: 04/03/2013, Revision: 25, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Over-The-Counter Monograph Drug User Fee Program (OMUFA)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-24 By FDA
  • Human medicines European public assessment report (EPAR): Datroway, datopotamab deruxtecan, Date of authorisation: 04/04/2025, Revision: 1, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-24
  • Pushclean Technology Plastik Sanayi Ve Ticaret Ltd. Sirketi - 709156 - 06/16/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-24 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.